Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16301430 | 0.92 | ABCG2 (0.49) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404164 | 0.92 | TP53 (0.60) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404177 | 0.91 | TP53 (0.59) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404171 | 0.88 | TP53 (0.65) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404176 | 0.88 | TP53 (0.56) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404172 | 0.88 | TP53 (0.58) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL10085985 | 0.88 | TP53 (0.56) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8403533 | 0.87 | TP53 (0.57) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404170 | 0.87 | TP53 (0.57) | TP53MAPTSMN1; SMN2ABCG2ABCB1 | |
| SCHEMBL8404166 | 0.86 | TP53 (0.55) | TP53MAPTSMN1; SMN2ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737461-B1 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-2431369-A2 | Carboline derivatives useful in the inhibition of angiogenesis | PTC Therapeutics, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2011150162-A1 | METHODS FOR TREATING VIRAL CONDITIONS | PTC THERAPEUTICS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-7767689-B2 | Carboline derivatives useful in the treatment of cancer | PTC THERAPEUTICS, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | PTC THERAPEUTICS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| WO-2008127714-A1 | ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127715-A1 | CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2005089764-A9 | CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS | PTC THERAPEUTICS INC (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227574-A2 | Administration of Carboline Derivatives Useful in the Treatment of Cancer and Other Diseases | VEGFA, FLT4, FLT1 | TP53 52/4885MAPT 3997/4885SMN1; SMN2 3261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.